TEVA PHARMACEUTICALS USA
- Teva and Heptares ink ~$400 million migraine deal The Pharma Letter - All news and articles
- UPDATE 1-Teva Pharmaceutical sets out Actavis funding after strong earnings update Reuters - Sectors - Healthcare
- Teva lays out $2.3 billion to acquire Mexico's Rimsa The Pharma Letter - All news and articles
- Teva Announces Approval of COPAXONE in Japan for the Prevention of Relapse of Multiple Sclerosis Business Wire Health News
- GSK False Ad Suit Over Teva's Generic Wellbutrin Frozen Law 360 Product Liability
- Largest Generic Drug Processor Facing Job Cuts Pharmpro News
- Teva to acquire 51% stake in genomic analysis firm Immuneering Pharmaceutical Business Review
- Analyst: Teva's Allergan Acquisition Likely to Yield Substantial Returns Pharmpro News
- Allergan may turn sights to Amgen or AbbVie with cash from Teva The Orange County Register - Santa Ana, CA
- Teva Escapes Merck's Patent Suit Over Generic Nasonex Law 360 Intellectual Property
Community Payment Ratings
Cortera is much more than an awesome business directory! It's an active community where real business people share the real deal on real businesses.
It's invaluable intel that's now available for FREE.
- Get the inside scoop with ratings and reviews on TEVA PHARMACEUTICALS USA
- Rate TEVA PHARMACEUTICALS USA on their payment behavior
- Ask your network about TEVA PHARMACEUTICALS USA with Cortera Circles
The information contained in this company profile is compiled from third party sources, including but not limited to public records, user submissions, and other commercially available data sources. These sources may not be accurate, complete, or up-to-date. Cortera makes no representations or warranties regarding, and assumes no responsibility for, the accuracy, completeness, or currency of the information contained herein.